Table 3 Efficacy endpoints after the third and sixth monthly erenumab administrations (n = 70)

  ≥ 30%

49 (70)

56 (80)

  ≥ 50%

37 (53)

49 (70)

  ≥ 75%

13 (18)

18 (26)

Response after dose increase in non-responder patients

–

–

6/21 (29)

MHD

21.1 ± 0.7

11.4 ± 0.9*

8.9 ± 0.7*

Conversion from chronic to episodic migraine

–

46 (66)

49 (70)

Conversion from medication overuse to non-overuse

–

40 (57)

43 (62)

Pain intensity (NRS)

8.6 ± 0.1

8.1 ± 0.1*

7.9 ± 0.1*

MIDAS

108.1 ± 11.2

54.5 ± 11.4*

51.0 ± 9.7*

HIT-6

65.9 ± 1.2

60.7 ± 1.2*

59.5 ± 1.4*

MSQ

62.7 ± 7.5

42.0 ± 7.6*

41.5 ± 7.7*

BDI-II

17.0 ± 1.4

13.2 ± 1.5

11.2 ± 1.6*

HDRS

14.3 ± 0.9

12.3 ± 1.5

10.5 ± 1.2*

HARS

17.1 ± 1.2

15.1 ± 1.7

13.2 ± 1.6*

PCS

33.2 ± 1.3

24.9 ± 1.8*

25.8 ± 2.1*

MOS Sleep Scale

24.7 ± 0.7

24.2 ± 0.8

22.9 ± 1.1*

ASC-12

6.7 ± 0.7

5.5 ± 0.8*

4.8 ± 0.8*

MIG-SCOG

9.9 ± 0.6

8.6 ± 0.6

8.8 ± 0.8